AU2013281582B2 - Pharmaceutical composition containing fimasartan and hydrochlorothiazide - Google Patents

Pharmaceutical composition containing fimasartan and hydrochlorothiazide Download PDF

Info

Publication number
AU2013281582B2
AU2013281582B2 AU2013281582A AU2013281582A AU2013281582B2 AU 2013281582 B2 AU2013281582 B2 AU 2013281582B2 AU 2013281582 A AU2013281582 A AU 2013281582A AU 2013281582 A AU2013281582 A AU 2013281582A AU 2013281582 B2 AU2013281582 B2 AU 2013281582B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
hydrochlorothiazide
tablet
fimasartan
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013281582A
Other languages
English (en)
Other versions
AU2013281582A1 (en
Inventor
Je Hak Kim
Ju Won Kim
Sang Yeop Kim
Kyung Wan Nam
Seo Hun PARK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boryung Pharmaceutical Co Ltd
Original Assignee
Boryung Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49783403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013281582(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boryung Pharmaceutical Co Ltd filed Critical Boryung Pharmaceutical Co Ltd
Publication of AU2013281582A1 publication Critical patent/AU2013281582A1/en
Application granted granted Critical
Publication of AU2013281582B2 publication Critical patent/AU2013281582B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2013281582A 2012-06-28 2013-04-30 Pharmaceutical composition containing fimasartan and hydrochlorothiazide Ceased AU2013281582B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2012-0070359 2012-06-28
KR20120070359A KR101414873B1 (ko) 2012-06-28 2012-06-28 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물
PCT/KR2013/003734 WO2014003305A1 (ko) 2012-06-28 2013-04-30 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물

Publications (2)

Publication Number Publication Date
AU2013281582A1 AU2013281582A1 (en) 2015-02-05
AU2013281582B2 true AU2013281582B2 (en) 2016-06-09

Family

ID=49783403

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013281582A Ceased AU2013281582B2 (en) 2012-06-28 2013-04-30 Pharmaceutical composition containing fimasartan and hydrochlorothiazide

Country Status (21)

Country Link
US (1) US9457094B2 (OSRAM)
EP (1) EP2868316B1 (OSRAM)
JP (1) JP6145506B2 (OSRAM)
KR (1) KR101414873B1 (OSRAM)
CN (2) CN104602676A (OSRAM)
AU (1) AU2013281582B2 (OSRAM)
BR (1) BR112014032764B1 (OSRAM)
CA (1) CA2877444C (OSRAM)
CL (1) CL2014003525A1 (OSRAM)
CO (1) CO7240413A2 (OSRAM)
ES (1) ES2654207T3 (OSRAM)
IN (1) IN2015DN00645A (OSRAM)
MX (1) MX351521B (OSRAM)
MY (1) MY165075A (OSRAM)
PE (1) PE20150607A1 (OSRAM)
PH (1) PH12014502876A1 (OSRAM)
RU (1) RU2613900C2 (OSRAM)
SG (1) SG11201408666SA (OSRAM)
UA (1) UA111434C2 (OSRAM)
WO (1) WO2014003305A1 (OSRAM)
ZA (1) ZA201409508B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105395552A (zh) * 2014-09-05 2016-03-16 南京华威医药科技开发有限公司 一种含非马沙坦及其盐的固体制剂
KR101545268B1 (ko) * 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2017091041A1 (ko) * 2015-11-26 2017-06-01 보령제약 주식회사 피마살탄의 신규 염
MX387327B (es) * 2016-01-27 2025-03-18 Boryung Pharm Composición farmacéutica para prevenir o tratar nefropatía diabética
KR102233673B1 (ko) * 2016-01-27 2021-03-30 보령제약 주식회사 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물
CN105784867B (zh) * 2016-03-28 2019-01-01 北京睿创康泰医药研究院有限公司 用于分析非马沙坦有关物质的hplc方法及这些杂质作参比标准的用途
KR102201396B1 (ko) * 2017-11-30 2021-01-11 보령제약 주식회사 피마살탄을 포함하는 약학적 조성물
KR20220162456A (ko) * 2021-06-01 2022-12-08 주식회사 보령 고혈압을 동반한 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물
CN120037195B (zh) * 2023-09-28 2025-11-28 浙江百代医药科技有限公司 一种硫辛酸药物组合物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4107831B2 (ja) * 2000-11-21 2008-06-25 第一三共株式会社 医薬組成物
HRP20040649B1 (en) * 2002-01-16 2012-12-31 Boehringer Ingelheim Pharma Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
KR100678421B1 (ko) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제
ES2523729T3 (es) 2006-06-16 2014-12-01 Lek Pharmaceuticals D.D. Composición farmacéutica que comprende hidroclorotiazida y telmisartán
WO2009058950A2 (en) 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
ES2364011B1 (es) * 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
KR101058284B1 (ko) 2010-01-22 2011-08-22 보령제약 주식회사 2-(2-ｎ-부틸-4-히드록시-6-메틸-피리미딘-5-일)-Ｎ,Ｎ-디메틸아세트아미드의 신규한 제조방법
TR201004754A1 (tr) * 2010-06-11 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Yeni Farmasötik Kombinasyonlar
CN102397278A (zh) * 2010-09-19 2012-04-04 鲁南制药集团股份有限公司 一种抗高血压药物组合物
CN102485228B (zh) * 2010-12-02 2015-06-10 鲁南制药集团股份有限公司 一种药物组合物及其用途
CN102485227B (zh) * 2010-12-02 2015-06-10 鲁南制药集团股份有限公司 一种药物组合物及其用途
CN102058602B (zh) * 2010-12-21 2013-04-10 中国药科大学 一种稳定的含氯沙坦钾和氢氯噻嗪的口服固体制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Encyclopedia of Pharmaceutical Technology (2007) pages 3657-3658 *
Journal of Cardiovascular Pharmacology. January 2012, vol. 59, no. 1, pages 84-91 *

Also Published As

Publication number Publication date
BR112014032764B1 (pt) 2021-12-07
US9457094B2 (en) 2016-10-04
US20150147394A1 (en) 2015-05-28
RU2613900C2 (ru) 2017-03-21
IN2015DN00645A (OSRAM) 2015-06-26
UA111434C2 (uk) 2016-04-25
MX2014015841A (es) 2015-07-17
CN110496122A (zh) 2019-11-26
JP2015525745A (ja) 2015-09-07
KR101414873B1 (ko) 2014-07-03
CA2877444A1 (en) 2014-01-03
CA2877444C (en) 2017-08-01
KR20140006233A (ko) 2014-01-16
PH12014502876B1 (en) 2015-02-23
ES2654207T3 (es) 2018-02-12
MY165075A (en) 2018-02-28
EP2868316A4 (en) 2016-02-17
SG11201408666SA (en) 2015-03-30
PE20150607A1 (es) 2015-05-16
PH12014502876A1 (en) 2015-02-23
JP6145506B2 (ja) 2017-06-14
BR112014032764A2 (pt) 2017-06-27
CN104602676A (zh) 2015-05-06
RU2015102553A (ru) 2016-08-20
CO7240413A2 (es) 2015-04-17
MX351521B (es) 2017-10-18
CL2014003525A1 (es) 2015-04-10
EP2868316B1 (en) 2017-12-06
WO2014003305A1 (ko) 2014-01-03
ZA201409508B (en) 2016-08-31
AU2013281582A1 (en) 2015-02-05
EP2868316A1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
CA2877444C (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
TWI325318B (en) Capsule and method of manufacturing the same
WO2017114227A1 (zh) 一种复方达格列净二甲双胍缓释片及其制备方法
CN106232144B (zh) 固体分散体
US20110136883A1 (en) Granulation of active pharmaceutical ingredients
KR20180104125A (ko) 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물
CA3168513A1 (en) Omecamtiv mecarbil tablet
KR20210084053A (ko) 엠파글리플로진 및 메트포르민을 포함하는 약제학적 복합제제 및 이의 제조방법
CN110121333B (zh) 含有苯并咪唑衍生物的制剂
US10583087B2 (en) Pharmaceutical composition for oral administration
JP2017523149A (ja) エドキサバンの医薬組成物
EP2799072A1 (en) Solid pharmaceutical composition comprising an antibiotic from the quinolone family and method for the production thereof
CN102137664B (zh) 具有被边界隔开的有效成分的固体药物制剂
TWI720115B (zh) 一種含有喹啉衍生物或其鹽的醫藥組成物的製備方法
KR20150075960A (ko) 펠렛이 매트릭스에 분산된 모사프리드 구연산염 함유 서방형 매트릭스 제제 및 이의 제조 방법
TWI726978B (zh) 一種含有喹啉衍生物或其鹽的藥物組成物
EP2153822A1 (en) Granulation of active pharmaceutical ingredients
JP2020147542A (ja) ダビガトランエテキシラートまたはその薬学的に許容される塩を含有する多層錠
JP2025524357A (ja) 多数の顆粒
TR2022013351A2 (tr) Li̇nagli̇pti̇n i̇hti̇va eden kompozi̇syonlarin üreti̇mi̇ne yöneli̇k yöntem
WO2024261701A1 (en) Edoxaban formulation.
KR20240115574A (ko) 라모세트론 또는 이의 약학적으로 허용되는 염을 함유하는 안정성이 향상된 신규 약학 조성물
CN119548499A (zh) 泮托拉唑药物组合物、其制备方法及应用
BG65912B1 (bg) Лекарствена форма на комбиниран препарат и метод за нейното получаване
HK1133817A1 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired